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Abstract: Introduction: Regarding scarce knowledge about bleeding in non-valvular atrial fibrillation (AF) patients with
simultaneous coronary artery disease (CAD) under triple anti-coagulant therapy, this study was carried out
to recognize the risk of hemorrhage and preventive programming. Material and Methods: In this performed
prospective, 150 consecutive patients with non-valvular atrial fibrillation and concurrent coronary disease, can-
didate for triple therapy with Asprin 80 mg, Clopidogrel 75 mg and Rivaroxaban 15 mg (in Shohada, Loghman,
Modarres, and Labafinezhad centers, in Tehran, Iran during Jan 2019 to Jan 2020 were enrolled and the incidence
rate of bleeding and compliance were evaluated for one month. Results: The results in this study demonstrated
that 87.3% had compliance and completely use three drugs. Bleeding occurred in 0.6% (4 patients), no major
bleeding , only one minor bleeding as GIB, three minimal cases (totally 4 bleeding cases), 3 cases with epistaxis,
7 patients with ecchymosis, 6 subjects with hematuria, no one required discontinuation of drug. Diabetes mel-
litus, hypertension, female sex, older age, higher HASBLED Score, and higher CHADS-VASC Score were related
to lack of compliance (P < 0.05). Conclusion: Incidence rate of bleeding in atrial fibrillation plus coronary con-
current patients, candidate for triple therapy with ASA, Clopidogrel and Rivaroxaban is low. Also the bleeding is
minor and the compliance is high showing that majority of cases use routinely these triple therapy regimen.
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1. Introduction
Atrial fibrillation (AF) is a common cardiac dysrhythmia seen
in nearly one percent of the general population, six percent in
elderly subjects, and nine percent in subjects aging from 80
to 89 years (1). Subjects with atrial fibrillation are at five-fold
higher risk of cardiovascular events leading to mortality, mor-
bidity, and health costs (1-3). Nearly 33 million AF cases are
present worldwide (4) and it is responsible for seventy per-
cent of non-valvular fibrillation cases (5). Vitamin-K antag-
onists such as warfarin are used for prevention of ischemic
events and optimal doses lead to INR (international normal-
ized ratio) range from 2 to 3 that is also accompanied with
severe bleeding (6-8). Nowadays there are four types of Non-
vitamin K antagonist (Non-VKA) anticoagulants with good
∗Corresponding Author: Mehdi Pishgahi; Address: Cardiology Department,
Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences,
Tehran, Iran. E-mail: mpishgahi.cr@gmail.com
efficacy but without need to INR assessment with lower in-
teractions (6, 9, 10). Dabigatran, Rivaroxaban, Apixaban, and
Edoxaban are these four approved therapeutics (5). Bleed-
ing is main adverse effect due to anti-coagulants (11-14). Ri-
varoxaban is Xa factor inhibitor used for prevention of my-
ocardial infarction in AF cases (11). But there is scarce data
about the gastrointestinal bleeding in Iranian Rivaroxaban
users as reported by Bigdeli and Sharif-Kashani (15). Regard-
ing the role of cytochrome oxidase enzymes and genetic vari-
ations according to the ethnic differences, some various re-
sults for the users may be expected (10). The importance
is higher in coronary artery disease cases for thromboem-
bolism prevention in atrial fibrillation, artificial valve cases,
and left ventricular systolic heart failure. These patients re-
ceive triple-therapy with addition of aspirin and P2Y12 re-
ceptor blocker and Rivaroxaban is the only approved case for
addition to dual therapy (12-14). Regarding scarce knowl-
edge about bleeding in AF patients with simultaneous CAD
(coronary artery disease) under treatment with rivaroxaban
beside other agents such as aspirin and Clopidogrel, this
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study was carried out to recognize the risk of hemorrhage
and evaluating compliance of drugs.
2. Material and Methods
In this cohort 150 consecutive patients with non-valvular
atrial fibrillation and concurrent coronary disease, candidate
for triple therapy with Asprin 80 mg (ABIDI Co. Tehran, Iran),
Clopidogrel 75 mg (ABIDI Co. Tehran, Iran), and Rivaroxa-
ban 15 mg (ABIDI Co. Tehran, Iran) in Shohadaa, Loghman,
Modarres, and Labafinezhad centers, in Tehran, Iran from
Jan 2019 to Jan 2020 were enrolled.
The study was approved by local ethical committee in
Shahid-Beheshti Medical Sciences University (Ethical code:
IR.SBMU.RETECH.REC.1398.144). Inclusion criteria were es-
tablished AF (atrial fibrillation) by electrocardiogram (ECG)
and echocardiography, established coronary artery disease
by EKG and angiography, and being candidate for triple ther-
apy with ASA, Clopidogrel and Rivaroxaban. The excluscri-
teria were renal/hepatic failure, Rivaroxaban hypersensitiv-
ity, GFR (Glomerular filtration rate) under 30 ml/min, active
bleeding, CHADS2-VASC scores of 0, and 1 in men and 0, 1,
and 2 in women according to EHRA2018 and European So-
ciety of Cardiology (ESC) 2019. The informed consent form
was received from participants.
At initiation of triple-therapy course the patients were en-
rolled and followed up till one month. The adverse effects
and drug tolerance were fulfilled in periodical assessments.
The cases were learned to attend if there were bleeding ear-
lier than visits. The incidence rate of major/minor bleeding
(by TIMI Bleeding Criteria as shown in Figure 1) and com-
pliance rates were determined. Compliance was assessed by
phone call and was defined as complete use of three drugs
during whole times. Also in the bleeding cases the HASBLED
scores were calculated and sub-analysis was done according
to it. Follow-up was after one month. Smokers were whom
smoke in last year (more than one pack / year). Diabetic
cases were controlled patients with diabetes mellitus accord-
ing to known history of hyperglycemia and diabetes thera-
peutics use.
Data analysis was done by SPSS version 21.0 software
among 150 patients. The utilized tests for sub-Group
analysis (assessment for background factors) in groups
were Kolmogorov-Smirnov, Chi-Square, Exact-Fisher, and
Independent-Sample-T and the P values under 0.05 were
considered statistically significant.
3. Results
The mean age of the participants in this work was 40.69
± 13.23 years. The mean age of the general population
and urologists was 35.8 ± 13.7 and 45.6 ± 10.6, respectively
(P=0.0001). 42.1% of the participants in the general pop-
ulation were under 30 years old (Table 1). 56.8% of the
general population respondents in this study had a univer-
sity degree (Table 2). Table 3 summarizes the prevalence
of the educational priorities among urologists and the gen-
eral population. In general, erectile dysfunction and STDs
were the most mentioned diseases as an educational pri-
ority (Table 3). 49.3% of the urologists considered erectile
dysfunction as an educational priority whereas 31% of the
general population mentioned it as a priority (P=0.0001).
STDs were an educational priority among 45.3% of urologists
while 35% of the general population mentioned it as a pri-
ority (P=0.003). Urolithiasis was an educational priority for
40% of the specialists and 26.8% of the general population
(P=0.0001). 37.3% of urologist participants and 29.8% of the
general population mentioned prostate cancer as a priority
(P=0.025). 37.3% of urologists also prioritized infertility while
17.8% of the general population considered infertility an ed-
ucational priority (P=0.0001). BPH was taken into account as
an educational priority by 34.5% of urology specialists and
23.0% of the general population (P=0.0001). Chronic pro-
statitis was considered an educational priority among 30.5%
of urologists and 11.3% of the general population (P=0.0001).
4. Discussion
Among 150 cases, there were 96 patients (64%) with sta-
ble IHD, 37 subjects (24.6%) with unstable angina/non-
STEMI (segment elevation myocardial infarction), and 17
cases (11.4%) with PRIMARY PCI (PPCI). The compliance rate
was 87.3%. As demonstrated in Figure 2, there were no ma-
jor bleeding cases. But one case with minor bleeding as
GI Bleeding, three minimal cases (totally 4 bleeding cases),
3 cases with epistaxis, 7 patients with ecchymosis, 6 sub-
jects with hematuria, and no one required discontinuation
of drug. In second week, there was one minor GIB leading to
4 units of hemoglobin reduction that underwent endoscopy
and received one unit of pack-cell with diagnosis of gastric
ulcer. Also, the aspirin and (Non-Oral vitamin K antagonist)
NOAC were discontinued for one week and also Clopido-
grel was discontinued two days and then these were contin-
ued again and after one week aspirin and Apixaban were re-
started. Among three minimal cases after endocolonoscopy
there were two cases with hemorrhoid and one with erosion.
In hemorrhoid cases the drugs was discontinued for one day
and in erosion case the Clopidogrel was continued but as-
pirin and Rivaroxaban were discontinued for three days and
then Rivaroxaban was replaced with Apixaban. The epistaxis,
hematuria, and ecchymosis were controlled spontaneously,
and drug was continued.
As shown in Table 1, the age, and HASBLED Scores were
significantly differed between those with and without toler-
ance (P=0.001). But CHADS-VASC Scores were not differed by
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Table 1: Age, HASBLED, and CHADS-VASC Scores and compliance.
Variable With compliance Without compliance P Value
Age 57.1 ± 12.1 72.3 ± 9.3 0.001
HASBLED 1.4 ± 0.5 2.7 ± 1.3 0.001
CHADS-VASC 2.7 ± 1.4 2.8 ± 1.4 0.280
Table 2: Categorical variables by compliance.
Variable With compliance Without compliance P Value
Male/female 107/24 11/8 0.032
Diabetes mellitus 31 (75.6%) 100 (91.7%) 0.008
Family history 38 (92.7%) 93 (85.3%) > 0.05
Smoking 64 (92.8%) 67 (82.7%) > 0.05
compliance (P=0.280). Compliance was assessed by phone
call and was defined as complete use of three drugs during
whole times.
As shown in Table 2, the female gender and diabetes melli-
tus were related to lack of compliance. But the family history
and smoking were not related to the compliance (P > 0.05).
As shown in Figure 3, the severity of involvement in angiog-
raphy was not related to compliance (P > 0.05).
5. Discussion
Anti-coagulant prophylaxis is an important point in the AF
patients and selection of the best drug with appropriate INR
and lower adverse effect is the main goal. Totally 87 percent
of subjects tolerated the triple therapy and completed the
course. We had no major bleeding but there were some cases
with minimal or minor bleedings. Some cases had hema-
turia, epistaxis, and ecchymosis without drug discontinua-
tion. Higher HASBLED and age, and female sex and presence
of diabetes mellitus history were related to lack of compli-
ance. Older age and also diabetes mellitus are expected ones
due to poly-pharmacy. Also, the female cases are more prob-
able to discontinue the drugs because of fear of side effects.
The association with higher HASBLED score can shows some
clinical relevance for preventive programming.
Fang et al (16) assessed 13,559 cases under warfarin ther-
apy and it was found that intra-cranial hemorrhage was main
bleeding adverse effect in survived users. This matter shows
the importance of alternative medications for warfarin as
well as Rivaroxaban. Fox et al (17) reported lower cranial
and gastrointestinal bleeding for Rivaroxaban versus war-
farin. The rate of GI bleeding in their study was 3.2 percent
for Rivaroxaban. In our study only there was one case with
minor GI bleeding. Patel et al (18) assessed 7131 AF cases and
it was found that Rivaroxaban had better emboli prevention
effect versus warfarin. However, in the study only adverse ef-
fects were assessed and the efficacies were not evaluated.
Habert et al (19) reported higher rate of GI bleeding in Ri-
varoxaban versus warfarin cases but the fatal and cranial
hemorrhage had lower in Rivaroxaban group. But in our
study only there was one case with GI bleeding. Lip et al
(5) reported same rate of GI bleeding in warfarin users and
those that received Rivaroxaban. But in our study only one GI
bleeding case was present and sub-analysis was impossible.
Yao et al (20) reported the rate of GI bleeding in Rivaroxaban
cases was 0.21 that was higher warfarin users. But in our GI
safety was not common in Rivaroxaban user cases.
Vimalesvaran et al (21) reported in their review study that
there is low risk of bleeding and mortality in Rivaroxaban
users that is in congruence with our study. Mendoza-Sanchez
and colleagues (22) reported better efficacy and lower ad-
verse effects by Apixaban. Also, conversely they reported
higher safety for warfarin versus Rivaroxaban. The cause of
this difference may be type of used scorings by them. Cole-
man et al (23) assessed 5517 diabetic cases and found that
warfarin and Rivaroxaban users had same side effect rates in-
cluding major bleeding cases. But we observed only minor
bleeding cases. Martinez et al (24) similarly reported good
safety and low rate and severity of GI bleeding cases by Ri-
varoxaban as same as our study.
6. Conclusion
According to the obtained results, it may be concluded that
the incidence of bleeding in atrial fibrillation plus coronary
concurrent patients who are the candidate for triple therapy
with ASA, Clopidogrel, and Rivaroxaban, is minimal. Further-
more, the compliance is good, and the majority of cases make
routine use of these triple therapy regimens. Small sample
size and high costs were among the main limitations in this
study. Further studies with larger sample population and
longer follow-up can develop more evidence on drug safety
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Figure 1: Diagram of TIMI Bleeding Criteria for bleeding measurement.
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Figure 2: Bleeding events in understudy patients.
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Figure 3: Angiography severity by compliance.
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